NY-AQARA
13.9.2022 09:01:43 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, introduced its Radiator Thermostat E1 to automate hydronic radiators including wall-mounted radiators, towel warmers and even warm floors, making the heating systems smarter for improved energy efficiency and comfort. This radiator thermostat supports most radiator valves with its M30*1.5mm thread connection and the provided adapters for RA, RAV and RAVL valves1. The Aqara Radiator Thermostat E1 is now available on European Amazon stores (France, Germany, Italy, Spain, UK), as well as via selective Aqara retailers in Europe2.
Based on the Zigbee 3.0 protocol, the Thermostat is expected to support the future-proofing Matter standard via an OTA update of the compatible, Zigbee 3.0-based Aqara hub3. The device is also compatible with major ecosystems and voice assistants such as HomeKit/Siri, Alexa, Google Home/Google Assistant, IFTTT, Home Assistant4 and more. Users can be reassured that the Thermostat works with their smart home setups of today and tomorrow.
Unlike many thermostatic radiator valves (TRVs) that rely solely on an internal sensor to measure the room temperature, which can be inaccurate due to the sensor’s proximity to the radiator, the Radiator Thermostat E1 can receive the temperature readings directly from a connected Aqara temperature sensor5 (including in HomeKit), and regulate the radiator based on the actual room temperature to increase comfort. Moreover, when connected to an Aqara Door and Window Sensor, the Thermostat can be configured to stop heating the room when any door or window is left open, in order to reduce energy waste. With the wide range of Aqara devices, users are able to create customized home automation that heats their homes only when it’s needed.
The Aqara Home app also offers various options for radiator automation. A smart schedule can be configured, allowing users to set the desired temperatures for different periods of time throughout the day, for example to set it to 5℃ during the daytime of weekdays when no one is at home, 25℃ for a relaxing evening after work, and 20℃ for a night of comfortable sleep. Geofencing is also possible, so the radiators will heat up the home before the family arrives. Another option is to automate the radiators based on local weather, and the heating will turn on automatically when the local temperature drops below a certain threshold.
Other features of the Radiator Thermostat include:
- Device grouping: multiple radiators in one room can be synchronized so that they work in a more efficient way, and make it possible to set different temperatures for each room;
- Multi-home management: in the case of having more than one home, users are able to manage the radiators in each home separately and set up individual automation such as geofencing-based automation;
- Anti-freeze mode: users can preset a temperature between 5℃ - 15℃ for this mode, and activate the mode easily when they are out of town to conserve energy while reducing the risk of pipe freezing;
- 12-month battery life: thanks to the Zigbee protocol and the energy-efficient hardware, 2 AA batteries will power the Thermostat for up to one year of use6.
To celebrate the launch, Aqara now offers a 10% discount for the Radiator Thermostat on its European Amazon stores in France, Germany, Italy, Spain and the UK with the promo code TRVE1UKEU. The code will be valid through September 15, 2022.
For more details of the Radiator Thermostat E1, please visit our website.
- This thermostat is only compatible with thermostatic valves, while manual, return temperature limiter (RTL) as well as monotube radiator systems are not supported. However in the majority of cases, it is possible to convert the existing radiator valve to a supporting one using an aftermarket adapter. Please consult professional installers or authorized Aqara retailers for more details.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the local retailer(s) for real time availability.
- Matter support may be unavailable by the time of the launch.
- Home Assistant support can be achieved using HomeKit Controller integration, which is developed by the Home Assistant community.
- Aqara’s Temperature and Humidity Sensor or TVOC Air Quality Monitor is required.
- Battery life may vary depending on the usage. The 1-year battery life is calculated based on the assumption of 8 operations per day for a heating season of 165 days and 1 operation every 2 weeks for the rest 200 days.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom